

What I Tell My Patients: Assisting Community-Based Oncologists and Surgeons in Discussion of Neoadjuvant Treatment Decisions with Their Patients with Early Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. A retrospective analysis of several NSABP clinical trials of adjuvant therapy demonstrated that locoregional recurrence rates have _____ over time.

 - a. Decreased
 - b. Increased
 - c. Remained unchanged
2. Data from randomized clinical trials suggest that a moderate level of exercise has no effect on the fatigue associated with breast cancer treatment.

 - a. True
 - b. False
3. According to the faculty, the risk of serious cardiac side effects for patients receiving an anthracycline-containing regimen for the treatment of breast cancer is approximately _____.

 - a. 25%
 - b. 10%
 - c. 3%
4. The benefits of neoadjuvant systemic therapy for breast cancer as discussed by the faculty include the following:

 - a. It permits breast conservation in patients who would otherwise require mastectomy
 - b. It allows evaluation of tumor response
 - c. In addition to eliminating tumor cells in the breast and nodes, it allows the physician to address possible metastasized cells earlier in the course of treatment
 - d. All of the above